Об авторах
Аманкулова Айтбу Амануловна, кандидат медицинских наук, врач гематолог, Национального центра онкологии и гематологии, Бишкек, Кыргызская Республика
Макимбетов Эмил Кожошович, доктор медицинских наук, зав. каф. онкологии Кыргызско-Российского Славянского Университета имени первого Президента Российской Федерации Б.Н. Ельцина, Бишкек, Кыргызская Республика
Amankulova Aitbu Amanulovna,Candidate of Medical Sciences, hematologist, National Center of Oncology and Hematology, Bishkek, Kyrgyz Republic
Makimbetov Emil Kozhoshovich, Doctor of Medical Sciences, Head of the Department of Oncology, Kyrgyz-Russian Slavic University named after the first President of the Russian Federation B.N. Yeltsin, Bishkek, Kyrgyz Republic
Аманкулова Айтбу Амануловна, медицина илимдеринин кандидаты, Улуттук онкология жана гематология борборунун гематологу, Бишкек, Кыргыз Республикасы
Макимбетов Эмил Кожошович, медицина илимдеринин доктору, Россия Федерациясынын биринчи президенти Б.Н. атындагы Кыргыз-Орус Славян университетинин онкология кафедрасынын башчысы. Ельцин, Бишкек, Кыргыз Республикасы
Список литературы
1. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chro
mosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660. doi:10.11
82/blood-2003-09-3032.
2. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;
102:1224–1231. doi: 10.1182/blood-2002-12-3637.
3. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Bone Marrow Transplant. 2008;42(Suppl. S2):S40–S46. doi: 10.1038/bmt.2008.282.
4. Suttorp M., Metzler M., Millot F. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
World J. Clin Oncol. 2020;11:308–319. doi: 10.5306/wjco.v11.i6.308.
5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol. Am. Soc. Hematol. Educ. Program.
2016;2016:598–604. doi: 10.1182/asheducation-2016.1.598.
6. Nitta M., Kato Y., Strife A. Incidence of Involvement of the B and T Lymphocyte Lineages in Chronic Myelogenous Leukemia.
Blood. 1985;66:1053–1061. doi: 10.1182/blood.V66.5.1053.1053.
7. Nogueira-Costa R., Spitzer G., Khorana S., Pham Q., Kantarjian H.M., Manning J.T., Ordonez N.G., Dicke K.A. T-cell Involve
ment in Benign Phase Chronic Myelogenous Leukemia. Leuk Res. 1986;10:1433–1439. doi: 10.1016/0145-2126(86)90010-X.
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor
cells with hemangioblastic characteristics. Blood. 2005;105:2733–2740. doi: 10.1182/blood-2004-07-2514.
9. Gunsilius E., Duba H.C., Petzer A.L. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-mar
row-derived endothelial cells. Lancet. 2000;355:1688–1691. doi: 10.1016/S0140-6736(00)02241-8.
10. Otten J., Schultze A., Schafhausen P. Blood outgrowth endothelial cells from chronic myeloid leukaemia patientsare BCR/ABL1
negative. Br. J. Haematol. 2008;142:115–118. doi: 10.1111/j.1365-2141.2008.07195.x.
1. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chro
mosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660. doi:10.11
82/blood-2003-09-3032.
2. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;
102:1224–1231. doi: 10.1182/blood-2002-12-3637.
3. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Bone Marrow Transplant. 2008;42(Suppl. S2):S40–S46. doi: 10.1038/bmt.2008.282.
4. Suttorp M., Metzler M., Millot F. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
World J. Clin Oncol. 2020;11:308–319. doi: 10.5306/wjco.v11.i6.308.
5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol. Am. Soc. Hematol. Educ. Program.
2016;2016:598–604. doi: 10.1182/asheducation-2016.1.598.
6. Nitta M., Kato Y., Strife A. Incidence of Involvement of the B and T Lymphocyte Lineages in Chronic Myelogenous Leukemia.
Blood. 1985;66:1053–1061. doi: 10.1182/blood.V66.5.1053.1053.
7. Nogueira-Costa R., Spitzer G., Khorana S., Pham Q., Kantarjian H.M., Manning J.T., Ordonez N.G., Dicke K.A. T-cell Involve
ment in Benign Phase Chronic Myelogenous Leukemia. Leuk Res. 1986;10:1433–1439. doi: 10.1016/0145-2126(86)90010-X.
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor
cells with hemangioblastic characteristics. Blood. 2005;105:2733–2740. doi: 10.1182/blood-2004-07-2514.
9. Gunsilius E., Duba H.C., Petzer A.L. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-mar
row-derived endothelial cells. Lancet. 2000;355:1688–1691. doi: 10.1016/S0140-6736(00)02241-8.
10. Otten J., Schultze A., Schafhausen P. Blood outgrowth endothelial cells from chronic myeloid leukaemia patientsare BCR/ABL1
negative. Br. J. Haematol. 2008;142:115–118. doi: 10.1111/j.1365-2141.2008.07195.x.
1. Champagne M.A., Capdeville R., Krailo M., et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chro
mosome-positive leukemia: Results from a Children’s Oncology Group phase 1 study. Blood. 2004;104:2655–2660. doi:10.11
82/blood-2003-09-3032.
2. Cwynarski K., Roberts I.A., Iacobelli S., et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003;
102:1224–1231. doi: 10.1182/blood-2002-12-3637.
3. Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT.
Bone Marrow Transplant. 2008;42(Suppl. S2):S40–S46. doi: 10.1038/bmt.2008.282.
4. Suttorp M., Metzler M., Millot F. Horn of plenty: Value of the international registry for pediatric chronic myeloid leukemia.
World J. Clin Oncol. 2020;11:308–319. doi: 10.5306/wjco.v11.i6.308.
5. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematol. Am. Soc. Hematol. Educ. Program.
2016;2016:598–604. doi: 10.1182/asheducation-2016.1.598.
6. Nitta M., Kato Y., Strife A. Incidence of Involvement of the B and T Lymphocyte Lineages in Chronic Myelogenous Leukemia.
Blood. 1985;66:1053–1061. doi: 10.1182/blood.V66.5.1053.1053.
7. Nogueira-Costa R., Spitzer G., Khorana S., Pham Q., Kantarjian H.M., Manning J.T., Ordonez N.G., Dicke K.A. T-cell Involve
ment in Benign Phase Chronic Myelogenous Leukemia. Leuk Res. 1986;10:1433–1439. doi: 10.1016/0145-2126(86)90010-X.
8. Fang B., Zheng C., Liao L., Han Q., Sun Z., Jiang X., Zhao R.C. Identification of human chronic myelogenous leukemia progenitor
cells with hemangioblastic characteristics. Blood. 2005;105:2733–2740. doi: 10.1182/blood-2004-07-2514.
9. Gunsilius E., Duba H.C., Petzer A.L. Evidence from a leukaemia model for maintenance of vascular endothelium by bone-mar
row-derived endothelial cells. Lancet. 2000;355:1688–1691. doi: 10.1016/S0140-6736(00)02241-8.
10. Otten J., Schultze A., Schafhausen P. Blood outgrowth endothelial cells from chronic myeloid leukaemia patientsare BCR/ABL1
negative. Br. J. Haematol. 2008;142:115–118. doi: 10.1111/j.1365-2141.2008.07195.x.
